New specific markers of @entity79 have been developed that allow the evaluation of bone formation (plasma levels of osteocalcin and bone alkaline phosphatases) or bone resorption (collagen crosslink levels in urine). These markers can be used to evaluate @entity79 . Their best application is currently in @entity8 , where there is a broad spectrum of @entity79 . In @entity1 with this disease, bone markers can obviate the need for bone biopsy. So far, bone alkaline phosphatase is the most sensitive and specific marker for predicting the type of @entity79 and therefore for deciding treatment in dialysed @entity1 , although it is not ideal. Bone markers have also allowed a dramatic improvement in the comprehensive approach to @entity604 with @entity1240 in @entity1 . Monitoring of the marked @entity79 , and its persistence, in older @entity1 after menopause may help in the design of treatment strategies for @entity170 . There is some hope that the measurement of urinary levels of collagen crosslinks will help to predict the clinical outcome of @entity170 with respect to @entity174 in postmenopausal @entity1 . Bone markers could, besides being a measurement of bone density, help to determine the optimal treatment of postmenopausal @entity1 . Bone markers could also be used to predict or ascertain the response to treatment of @entity170 , but few data are currently available to judge the routine usefulness of these new applications.

Markers of XXXX in metabolic bone disease.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal osteodystrophy'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures'] @entity604 :: ('MESH:D016301', 'Disease') :: ['bone loss'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['increase in bone turnover', 'bone abnormalities', 'bone disease', 'bone remodelling'] @entity1240 :: ('MESH:D019588', 'Disease') :: ['aging']
@entity79 :: (MESH:D001847,Disease) :: ['bone remodelling']
